Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Other(3)

Detailed Status

unknown3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

unknown375%
completed125%

Recent Activity

0 active trials
Showing 4 of 4
unknown

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

NCT03724097
unknown

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

NCT03521245
unknown

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

NCT03430414
completednot_applicable

myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies

NCT00213629

Clinical Trials (4)

Showing 4 of 4 trials
NCT03724097

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

Unknown
NCT03521245

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

Unknown
NCT03430414

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

Unknown
NCT00213629Not Applicable

myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4